A share price of Applied Therapeutics Inc [APLT] is currently trading at $9.59, down -0.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The APLT shares have gain 10.87% over the last week, with a monthly amount glided 13.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 26, 2024, and set its price target to $12. On February 22, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $12 on the stock. Barclays downgraded its rating to a Equal Weight and decreased its price target to $7 on January 04, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $10 on August 27, 2021. In a note dated October 08, 2020, Truist initiated an Buy rating and provided a target price of $85 on this stock.
Applied Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.79 and $10.62. Applied Therapeutics Inc [NASDAQ: APLT] shares were valued at $9.59 at the most recent close of the market.
Analyzing the APLT fundamentals
Gross Profit Margin for this corporation currently stands at 3.79% with Operating Profit Margin at 437.36%, Pretax Profit Margin comes in at 887.73%, and Net Profit Margin reading is 887.73%. To continue investigating profitability, this company’s Return on Assets is posted at -1.76, Equity is -5.83 and Total Capital is -12.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.24 points at the first support level, and at 8.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.93, and for the 2nd resistance point, it is at 10.28.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Applied Therapeutics Inc [NASDAQ:APLT] is 1.06. In addition, the Quick Ratio stands at 1.06 and the Cash Ratio stands at 1.0. Considering the valuation of this stock, the price to sales ratio is 108.69, the price to book ratio is 189.38.
Transactions by insiders
Recent insider trading involved Funtleyder Leslie D., Chief Financial Officer, that happened on Aug 22 ’24 when 13530.0 shares were sold. Chief Medical Officer, Perfetti Riccardo completed a deal on Aug 22 ’24 to sell 22681.0 shares. Meanwhile, President and CEO Shendelman Shoshana sold 0.36 million shares on Aug 13 ’24.
